Agreement is first step towards collecting -- and analyzing -- data designed to provide better, more personalized cancer treatment
WASHINGTON and HAMBURG, Germany, July 31 /PRNewswire-USNewswire/ -- The field of personalized cancer research and treatment grows with each day. And a new partnership with Washington's largest biomedical research organization and an international research and biobanking company is contributing to that growth.
Georgetown University Medical Center announced today a partnership with Indivumed GmbH, based in Hamburg, Germany, designed to analyze complex clinical molecular signatures from cancer patients, enabling researchers and physicians to better diagnose and tailor cancer treatments for individual patients. The partnership builds upon a one-year agreement currently in place at Georgetown that established a high-quality tumor biobank and clinical database for pancreatic cancer and which, recently, also includes cancer of the breast and colon.
The expanded collaboration will grow to include a clinical database of prostate, glioblastoma and renal cancer. Together, the institutions expect to establish a robust portfolio of research collaborations, supported by a state-of-the-art biobanking infrastructure and protocol, using Indivumed's established scientific approach, and a multidimensional, integrated clinical and molecular database of cancer.
"Integrating scientific, medical, and technological expertise and assets will transform our ability to analyze complex clinical data relating to specific diseases, employing a more comprehensive, system-level approach to how we treat patients," says Howard J. Federoff, M.D., Ph.D., Executive Vice President for Health Sciences at GUMC. "We're starting with cancer, and hope this kind of research will lead to better, more individually targeted treatments."
The agreement will expand upon the Indivumed Biobank protocol already
begun at Georgetown University Hospita
Copyright©2008 PR Newswire.
All rights reserved